NEUREN PHARMACEUTICALS LIMITED GENERAL MEETING
Tuesday, 29 August, 2017
RESULT OF GENERAL MEETING (ASX REPORT)As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.
Manner in which the securityholder directed the proxy vote (as at proxy close): | Manner in which votes were cast in person or by proxy on a poll (where applicable) | |||||||
Resolution | Votes For | Votes Against | Votes Discretionary | Votes Abstain | For | Against | Abstain ** | |
1 | APPROVAL BE GIVEN TO THE COMPANY TO ISSUE 9,677,419 SHARES TO ESSEX CASTLE LIMITED AT AN ISSUE PRICE OF $0.062 PER SHARE. | 674,776,573 | 1,877,597 | 13,761,747 | 4,500 | Passed on a show of hands | Passed on a show of hands | Passed on a show of hands |
2 | APPROVAL BE GIVEN TO THE COMPANY TO ISSUE 1,290,323 SHARES TO KAREN ELIZABETH TREAGUS ATF TREAGUS FAMILY TRUST AT AN ISSUE PRICE OF $0.062 PER SHARE. | 713,467,380 | 3,075,905 | 13,761,747 | 0 | Passed on a show of hands | Passed on a show of hands | Passed on a show of hands |
3 | APPROVAL BE GIVEN TO THE COMPANY TO ISSUE 1,290,323 SHARES TO LARRY GLASS AT AN ISSUE PRICE OF $0.062 PER SHARE. | 764,613,172 | 2,040,998 | 13,761,747 | 4,500 | Passed on a show of hands | Passed on a show of hands | Passed on a show of hands |
4 | APPROVAL IS GIVEN TO THE PRIOR ISSUE ON 11 AND 12 JULY 2017 OF 11,935,485 SHARES AT AN ISSUE PRICE OF $0.062 PER SHARE | 736,359,583 | 2,857,597 | 3,116,585 | 4,500 | Passed on a show of hands | Passed on a show of hands | Passed on a show of hands |
5 | APPROVAL IS GIVEN TO THE PRIOR ISSUE TO LANSTEAD CAPITAL L.P. ON 18 JULY 2017 OF 161,290,323 SHARES AT AN ISSUE PRICE OF $0.062 PER SHARE AND 8,064,516 SHARES AS CONSIDERATION FOR ENTERING A SHARING AGREEMENT. | 682,658,471 | 2,857,597 | 14,899,849 | 80,004,500 | Passed on a show of hands | Passed on a show of hands | Passed on a show of hands |
** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item
Printed: 29/08/2017 10:20:25PM
This report was produced from the Link Market Services System
Page 1 of 1
Neuren Pharmaceuticals Limited published this content on 29 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 29 August 2017 02:32:08 UTC.
Original documenthttp://www.neurenpharma.com/irm/PDF/1695_0/ResultsofMeeting
Public permalinkhttp://www.publicnow.com/view/EE1A369D76687A624EEEF2FCB0C2F8AD1C9726BA
